Dr. Finn Discusses Palbociclib for Patients With Advanced Breast Cancer

Richard S. Finn, MD
Published: Tuesday, Feb 10, 2015



Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that led to the FDA approval of palbociclib in combination with letrozole as a first-line treatment for patients with ER-positive, HER2-negative, advanced breast cancer.

Early studies showed that ER-positive, HER2-negative breast cancer models seem to be uniquely sensitive to CDK 4/6 inhibition, Finn notes. Additionally, there was a synergistic inhibition of growth of these models when combined with anti-estrogens.

The global, open-label PALOMA-1 study randomized 165 postmenopausal women with ER-positive, HER2-negative breast cancer to palbociclib with letrozole or letrozole alone. The median progression-free survival (PFS) with palbociclib was 20.2 versus 10.2 months for letrozole alone (HR = 0.49; P = .0004).

In addition to the approval, early results from PALOMA-1 culminated in a breakthrough therapy designation for palbociclib. Following the FDA's decision, palbociclib became the first approved CDK 4/6 inhibitor.
 


Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that led to the FDA approval of palbociclib in combination with letrozole as a first-line treatment for patients with ER-positive, HER2-negative, advanced breast cancer.

Early studies showed that ER-positive, HER2-negative breast cancer models seem to be uniquely sensitive to CDK 4/6 inhibition, Finn notes. Additionally, there was a synergistic inhibition of growth of these models when combined with anti-estrogens.

The global, open-label PALOMA-1 study randomized 165 postmenopausal women with ER-positive, HER2-negative breast cancer to palbociclib with letrozole or letrozole alone. The median progression-free survival (PFS) with palbociclib was 20.2 versus 10.2 months for letrozole alone (HR = 0.49; P = .0004).

In addition to the approval, early results from PALOMA-1 culminated in a breakthrough therapy designation for palbociclib. Following the FDA's decision, palbociclib became the first approved CDK 4/6 inhibitor.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x